Pharma Company Cipla is all set to launch the anti-viral drug Favipiravir for the treatment of COVID-19 patients.<br />'' <br />''A top government research institute, Council of Scientific and Industrial Research,CSIR has played an important role in the process by transferring the cost effective technology to Cipla.<br />'' <br />''Director CSIR-IICR, Dr. S Chandrashekhar said, the technology provided by the Institute is very efficient and affordable. He said, it allows the company to make large quantities of drugs within a short span of time.<br />'' <br />''Director General of CSIR, Dr. Shekhar Mande said, CSIR is working with the industry in developing products for mitigation of Covid-19. He said, partnership with Cipla is an example that CSIR is committed in bringing repurposed drugs on a fast track.<br />'' <br />''CSIR-Indian Institute of Chemical Technology developed a cost effective process and transferred the technology to the Cipla Company.<br />'' <br />''Anti-viral drug Favipiravir has shown promising results in clinical trials for treatment of Covid-19 patients especially in the mild and moderate patients.<br />'' <br />''<span style="color: #222222;">Drug Controller General of India has given restricted emergency use for Favipiravir in the country.</span><br />